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Abstract
Objective: To measure plasma N-terminal fragments of pro-B-type natriuretic peptides (NT-
proBNP) and cardiac troponin T (cTnT) concentration in hospitalized dogs and relate these mark-
ers to underlying conditions and evaluate their potential as prognostic markers in dogs with sys-
temic inflammatory response syndrome (SIRS).
Design: Prospective, observational, clinical study.
Setting: Emergency department of a university teaching hospital.
Animals: Sixty-nine dogs with SIRS examined in the emergency department were prospectively
studied. Patient age ranged from 5months to 15 years, andweight ranged from 5.5 to 75 kg.
Measurements andMain Results:Blood samples were obtained at presentation, during hospital-
ization until discharge or death, and at a “control” visit (T1m) at least 1 month after hospital dis-
charge. NT-proBNPwas assayedwith a commercially available canine ELISA,while cTnTwasmea-
sured with an automated immunoassay previously used in dogs. A correlation procedure, mixed
procedure on a linear model, and a logistic procedure were performed. Forty-four patients sur-
vived, 19 of which had control visits. cTnT concentrations were significantly higher than T0 and
T1m at T12, T24, and T72. In 28 dogs, cTnTwas detected during hospitalization, but cTnTwas not
detected in any dog at the control visits. Higher concentrations of cTnT were negatively associ-
atedwith survival, irrespective of disease category. NT-proBNP concentrationswere significantly
higher than T0, T6, T12, and T1m at T24, T72, and T120, but were not associated with survival.
Conclusions: NT-proBNP and cTnT increased significantly in dogs with SIRS, regardless of the
underlying disease process. Nonsurvivors displayed significantly higher cTnT concentrations dur-
ing hospitalization.
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1 INTRODUCTION
The systemic inflammatory response syndrome (SIRS) characterizes
the systemic repercussions of inflammation. The list of underlying
Abbreviations: BNP, B-type natriuretic peptides; cTn, cardiac troponin; cTnI, cardiac troponin I; cTnT, cardiac troponin T; GDV, gastric dilation and volvulus; NT-proBNP, N-terminal fragment of
pro-BNP; SIRS, systemic inflammatory response syndrome; T‘X’, values obtained ‘X’ hours after presentation to the emergency department; T1m, ‘control’ visit at least 1month after discharge.
c©Veterinary Emergency and Critical Care Society 2019
causes of SIRS is diverse, including sepsis, trauma, and sterile inflam-
matory conditions such as pancreatitis.1 The criteria for SIRS are
based on defined changes in clinical (body temperature, heart rate,
and respiratory rate) and hematologic (leukocyte counts, presence
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TABLE 1 Clinical criteria for the diagnosis of SIRS (modified from
Hauptman et al,2 with alterations in white blood cell count to adhere
with the reference ranges of the clinical laboratory and temperature
ranges as applied in clinics)
Parameter Limit Unit
Heart frequency >120 bpm
Respiratory rate <20 rpm
Temperature <38 or>39 ◦C
Leukocytosis/leukopenia >16,000 or<5,000 /𝜇L
Left shift on blood smear >3 %
of a left shift) variables (Table 1).2 The diagnosis of SIRS recognizes
the presence of clinical signs compatible with systemic inflammation,
but the criteria are overly sensitive and poorly specific.2 Cardiac
dysfunction secondary to systemic inflammation has been reported
in human medicine, and is also known as myocardial hibernation.3,4
Myocardial hibernation has been reported in critically ill human
patients and studied in dogs with experimentally induced sepsis.4–7 It
is characterized by increased end-diastolic and end-systolic ventric-
ular volumes,8 and systolic3 and diastolic7 ventricular dysfunction.5
Whether myocardial hibernation serves as a protective mechanism of
the body during systemic inflammation, or whether it has a negative
impact on survival is unknown.5,9 Myocardial hibernation has been
associated with increased blood concentrations of cardiac troponins
(cTn)10,11 and natriuretic peptides12–14 in people with SIRS, and some
studies have found concentrations of cTn and the N-terminal portion
of pro-brain natriuretic peptide (NT-proBNP) to be correlated with
the degree of cardiac dysfunction and with plasma concentrations
of inflammatory cytokines.9,15 Very little is known about myocardial
hibernation in dogs with naturally occurring disease, although it is
likely to occur.16,17 Recent data suggest that plasma concentrations
of cardiac biomarkers are increased in dogs with SIRS.18–20 As these
cardiac biomarkers may help in the diagnosis of cardiac dysfunction
and the evaluation of prognosis in people with SIRS,9,21,22 they may
also be useful to evaluate dogs with SIRS.
Cardiac troponins T and I (cTnT and cTnI, respectively) are sen-
sitive and specific for the detection of myocardial ischemic necro-
sis or reversible myocardial injury, and increased plasma cTnT and
cTnI concentrations are associated with a poorer prognosis in criti-
cally ill people.23,24 Cardiac troponins have been studied in veterinary
patients with cardiac disease,25 and are also increased and associated
with poor prognosis in other syndromes such as gastric dilation and
volvulus (GDV),25,26 trauma,25,27 infections,28–32 and SIRS.19,20,33
Brain natriuretic peptide (BNP) and NT-proBNP are quantitative
markers of ventricular wall stress with high sensitivity and speci-
ficity for cardiac insult.12 Several studies have associated increases
in plasma BNP and NT-proBNP in people with sepsis and SIRS with
myocardial hibernation and poor prognosis.9,12,13,15 In veterinary
medicine, increased plasma NT-proBNP concentrations have been
demonstrated in dogs with babesiosis and in dogs with traumatic,
neurological, and gastrointestinal diseases.32,34 We hypothesized that
plasma cTnT and NT-proBNP would increase during hospitalization,
vary in magnitude according to the underlying etiology, and serve as
a prognostic marker in canine patients with SIRS.
2 MATERIALS AND METHODS
All dogs thatwere examined in the emergency service of theUniversity
of Liège between January and August 2010were considered for inclu-
sion. Dogs were enrolled if SIRS was diagnosed based on the suspicion
of an underlying disease process known to trigger the systemic inflam-
matory response and the finding of 2 or more abnormalities of the fol-
lowing clinical (temperature, heart rate, and respiratory rate) and basic
laboratory parameters (leukocyte counts).2 The cutoff values forwhite
blood cell counts were modified from the original paper to adhere
with the reference ranges of our own clinical laboratory (Table 1) and
the limits of normal rectal temperature were between 38 and 39◦C.
Approval for this project was obtained from the ethics committee
(approval number 1709), and informed consent was obtained from the
owners of each dog. Exclusion criteria included a weight <5 kg and
animals that were considered too unstable to sustain any additional
or unnecessary stress. Patients were grouped into 7 different disease
categories: patients with neoplastic disease (N), infectious disease (I),
GDV, gastrointestinal disease (GI), trauma (T), renal disease (R), and
miscellaneous causes (M). Since concentrations of plasma NT-proBNP
can be influenced by renal function, patients with renal insufficiency
(defined as azotemia or oligo-anuria that was unresponsive to fluid
therapy) were excluded from NT-proBNP analysis.35 Although plasma
cTn concentrations also can be influenced by renal function, the sever-
ity of renal failure does not correlatewith cTn concentrations,36,37 and
cTn analysis remains useful in identifying myocardial injury in people
with renal disease.38–40 Similarly, plasma cTn concentrations can iden-
tify human patients with poorer prognosis despite concurrent renal
failure or requirement for hemodialysis.38,41–46 Based on these find-
ings, we did not exclude patients with renal impairment from plasma
cTnT analysis.
Baseline plasma concentrations of cTnT and NT-proBNP were
assessed on blood sampled prior to starting any treatment (T0), and
on samples obtained after 6 (T6), 12 (T12), 24 hours (T24), and every
other day thereafter (T72, T120, etc.) until hospital discharge or
death. Short-term survival was defined as patient discharge from the
hospital, while long-term survival was defined as the patient being
alive 1month after discharge from the hospital. All long-term survivors
were invited to a recheck “control” examination occurring between
1 month and 1 year after hospital discharge, where blood was again
collected for analysis. All blood samples were divided into EDTA (4mL)
and serum (2 mL) tubes that were centrifuged and separated within
15minutes, with the serum or plasma stored at –80◦C until analysis.
A commercial electrochemiluminescence kit,∗ with a lower limit of
detection of 0.010 ng/mL, a limit of linearity of 25.00 ng/mL, and a
coefficient of variation less than 5% for values above 0.06 ng/mL, was
used tomeasure serum cTnT.47 The kit detected 2 epitopes of the cen-
tral part of human cTnT (125–131 and 135–147), which are highly
conserved in canine cTnT (one substitution in the first epitope and
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100% homology in the second), and has previously been used in vet-
erinary research.47,48 Reported values in healthy dogs are less than
0.010 ng/mL.27,49
A commercially available sandwich enzyme immune assay† with an
upper limit of detection of 3,000 pmol/L was used to measure NT-
proBNP. Patient plasma and an immunoaffinity purified sheep detec-
tion antibody conjugated to horseradish peroxidase were incubated
for 5 hours at 20◦C in microtiter plates with capture antibody (anti-
NT-proBNP)bound to thewells. Thewellswere thenwashedand tetra-
methylbenzidine was added and incubated for 40minutes, after which
a stop solution was added and bound NT-proBNP was quantified by
an ELISA plate reader. All plates were run with calibration and con-
trol solutions, yet for financial reasons only the first plate was run in
duplicate.
2.1 Statistical methods
Statistical analysis was performed using a commercially available
statistics program.‡ A Shapiro–Wilk and Kolmogorov–Smirnov test
(univariate procedure) and normality QQplots were performed on the
raw data and on logarithmic-transformed data. For both cTnT and NT-
proBNP, the logarithmically transformed data were used for analysis
after identification of a nearly normal distribution of the residues on
the QQplots. A mixed procedure on a generalized linear model was
used to assess the relationship of measured clinical parameters to car-
diac biomarkers. As the data were taken repeatedly over time on the
same animals, there is a possible correlation between successive data.
This correlation structure is reflected in the linear mixed model used
(MIXED procedure, repeated by time). Correlation between different
biomarkers was tested (CORR procedure). A logistic analysis (LOGIS-
TIC procedure) was performed in order to evaluate the association of
plasma cardiac biomarker concentrations with survival to discharge.
Only dogs that survived, died of natural causes, or were euthanized
for prognostic reasons were included in the assessment of prognostic
value of the evaluated parameters. Statistical significance was set at a
P-value< 0.05.
3 RESULTS
Fifty-eight purebred and 11 mixed-breed dogs were included in the
study. The most commonly represented breeds were Bernese Moun-
tain Dog (n = 8), German Shepherd Dog (n = 6), Great Dane (n = 4),
Jack Russell Terrier (n = 4), and Belgian Shepherd Dog (n = 3). There
were 38 male (29 intact and 9 neutered) and 31 female (17 intact and
14 neutered) dogs with a median age of 6.5 years (ranging between 7
months and 15.2 years) and with a median weight of 30.3 kg (ranging
from 5.5 to 75 kg). Patients were categorized by disease (N = 13; I =
12; GDV = 11; GI = 5; T = 6; R = 3; and M = 19). Outcome and follow-
up of our studied population has been represented in a flow diagram
(Figure 1). Forty-four patients were discharged, 8 died during hospi-
talization, and 17 dogs were euthanized (8 for prognostic, 7 for finan-
cial, and 2 for unspecified reasons). Thirty-four patients were still alive
more than1month after discharge and19werepresented for a control
F IGURE 1 Flow diagram of the disposition of dogs with SIRS
throughout the study. D, deceased; P, euthanized for prognostic
reasons; F, euthanized for financial reasons; U, euthanized for unclear
reasons; R, diedmore than amonth after discharge yet before a
control visit was performed; L, lost to follow-up
F IGURE 2 Scatter plots of serum concentrations of cTnT at
different time points in hospitalized dogs with SIRS. The red line
indicates themedian value
visit. Of the dogs that did not have a follow-up visit, 5 died from related
causes before the scheduled visit (including continued gastrointesti-
nal illness in 2 dogs, aspiration pneumonia secondary to a megaesoph-
agus, worsening hepatocutaneous syndrome, and tumor recurrence
with secondary hemoabdomen in 1 dog each), 5 owners declined, and
5 dogs were lost to follow-up.
3.1 Biomarker analysis
Plasma concentrations of cTnT and NT-proBNP both changed signifi-
cantly over time (P< 0.0001). Concentrations of cTnT andNT-proBNP
at each timepoint are displayed in Figures 2 and 3, respectively.
Twenty-eight of 69 dogs had at least 1 time point during hospital-
ization at which cTnT was detectable, while none of the dogs had
measurable cTnT concentrations at the control visit. Plasma cTnT
concentration was significantly higher at T12, T24, and T72 compared
to concentrations at presentation and at the control visit (Table 2).
Plasma NT-proBNP concentrations were measurable in all dogs at
all timepoints. Plasma NT-proBNP concentrations were significantly
higher at T24, T72, and T120 compared to T0, T6, T12, and T1m.
Median concentrations did not differ significantly between T24
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F IGURE 3 Plasma concentrations of NT-proBNP at different time
points in dogs with SIRS. The central line of the box plot indicates the
median value, the upper and lower line of the box plot illustrate the
range of the 25% and 75% of the values, and the outer lines at the end
of the vertical lines indicate the 95% and 5% range of the recorded
values
(661.39 [60.77–3,000] pmol/L), T72 (888.81 [76.58–3,000] pmol/L),
and T120 (737.14 [0–3,000] pmol/L; Table 3).
3.2 Correlation of biomarkers with underlying
disease, prognosis, and each other
Statistical analysis did not identify any influence of the underlying dis-
ease category on cTnTandNT-proBNPconcentrations (P=0.1618 and
0.084, respectively). Regardless of the specific timepoint, detectable
F IGURE 4 Scatter plot of serum cardiac troponin T (cTnT)
concentrations in survivors and nonsurvivors at different timepoints;
S, survivor; NS, nonsurvivor (natural death or euthanized for
prognostic reasons). The red line indicates themedian value
cTnT concentrations (P = 0.0106) were associated with poor progno-
sis (Figure 4). In contrast, NT-proBNP concentrations were not corre-
lated with survival to discharge (P = 0.5091, Figure 5). Finally, concen-
trations of cTnT and NT-proBNP were significantly and mildly corre-
lated (P< 0.001, with R= 0.2913).
4 DISCUSSION
This study demonstrated changes in cardiac biomarkers during hos-
pitalization in a population of canine patients with SIRS. Troponin
TABLE 2 P-values for cTnT concentrations between different time points in all canine SIRS patients
T0 T6 T12 T24 T72 T120 T1m
T0 1 0.0501 0.0002* 0.0004* 0.0231* 0.8514 0.0866
T6 0.0501 1 0.0677 0.0748 0.4441 0.368 0.0022*
T12 0.0002* 0.0677 1 0.9257 0.514 0.0572 <0.0001*
T24 0.0004* 0.0748 0.9257 1 0.4769 0.0536 <0.0001*
T72 0.0231* 0.4441 0.514 0.4769 1 0.174 0.001*
T120 0.8514 0.368 0.0572 0.0536 0.174 1 0.1634
T1m 0.0866 0.0022* <0.0001* <0.0001* 0.001* 0.1634 1
Significant differences are indicated in bold with an asterisk (*).
TABLE 3 P-values for NT-proBNP concentrations between different time points in all canine SIRS patients
T0 T6 T12 T24 T72 T120 T1m
T0 1 0.2712 0.2125 0.008* 0.0004* 0.005* 0.9357
T6 0.2712 1 0.8849 0.0003* <0.0001* 0.0007* 0.4015
T12 0.2125 0.8849 1 0.0002* <0.0001* 0.0005* 0.3475
T24 0.008* 0.0003* 0.0002* 1 0.2061 0.2321 0.0626
T72 0.0004* <0.0001* <0.0001* 0.2061 1 0.7928 0.0063*
T120 0.005* 0.0007* 0.0005* 0.2321 0.7928 1 0.0155*
T1m 0.9357 0.4015 0.3475 0.0626 0.0063* 0.0155* 1
Significant differences are indicated in bold with an asterisk (*).
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F IGURE 5 Plasma concentrations of NT-proBNP in survivors and
non survivors at different time points; S, survivor; NS, nonsurvivor
(natural death or euthanized for prognostic reasons). The red line
indicates themedian value
concentrations rise within 8 hours after an initial insult, and remain
increased for over 50 hours in people and dogs.10,50–52 cTnT values in
the cohort of dogs in this report were detectable in 28 dogs during
hospitalization, with concentrations significantly higher at T12, T24,
and T72, compared to concentrations at presentation and at the con-
trol visit. Although the clinical nature of this study on dogs suffering
fromdifferent diseases does not allowus to identify the exact timing of
the original insult in the majority of dogs, the timing of the changes in
cTnT concentrations appear to agree with the rapid rise and sustained
increase described in other reports. In contrast, at the control visit, all
dogs had undetectable cTnT concentration (<0.01 ng/mL). A study in
dogs with GDV described similar findings, with no significant changes
in cTnT concentrations immediately after surgery but increased con-
centrations on the 2 days after presentation.25,26 A study evaluating
cTnI concentrations in dogs with SIRS identified a higher prevalence of
increased cTnI concentrations at presentation (35/60 dogs) and dur-
ing hospitalization, but also did not find significant variations from day
to day.19 A study comparing cTnT and cTnI in dogs with SIRS admit-
ted to an ICU found a higher prevalence of increased cTnI concentra-
tions. This difference in detection rate can be explained by the lower
sensitivity of cTnT compared to cTnI to detect myocardial lesions, or
by the timing of sampling compared to the start of the disease process
(as admission to the ICU likely takes place later than admission to an
emergency department).20 The use of a cTnI assay in the present study
may have resulted in the detection of increased concentrations in a
larger proportion of SIRS patients, but cTnT was chosen for financial
reasons.26,28
NT-proBNP changed significantly over time, with concentrations
at T24, T72, and T120 significantly higher than concentrations at T0,
T6, T12, and the control visit. Most of the research performed in vet-
erinary medicine on NT-proBNP has focused on cardiac disease.53–55
A recent study evaluating BNP in dogs with noncardiac disease (eg,
neurological and gastrointestinal disease) demonstrated a moder-
ate increase of natriuretic peptides in these patients.34 BNP and
NT-proBNP concentrations cannot be directly compared. However,
as SIRS has a high potential to induce cardiac effects in human
medicine, the more markedly increased NT-proBNP concentrations
in our study focused on dogs with SIRS compared to this previous
study therefore do not seem surprising.35 Finding higher concentra-
tions at T24, T72, and T120 is in agreement with studies on SIRS
and sepsis in human patients. The time point with the highest plasma
NT-proBNP measurement varied across studies in people, from the
day of admission to day 2 and day 5 after admission,22,56 which
is probably due to the difficulty in determining the time of onset
of the disease. Nevertheless, peak concentrations are likely to be
found more than 2 days after hospitalization in people.9,15,21 Unfor-
tunately, the clinical setting of this study prevented determination
of the exact time the insult triggering SIRS occurred for the major-
ity of dogs. The kinetics observed in this cohort do confirm that NT-
proBNP is expected to rise during the first days of hospitalization in
dogs with SIRS. Increased concentrations of NT-proBNPwhen screen-
ing for occult cardiac disease should therefore be interpreted care-
fully in patients that also have SIRS. Whether increased cTnT and NT-
proBNP concentrations are indicative of myocardial hibernation in
dogswith SIRS cannot be concluded from this paper butmerits further
investigation.
Detectable cTnT concentrations during hospitalization were
associated with poor short-term prognosis. Cardiac troponin T
and I are well-accepted prognostic biomarkers in human intensive
care units.10,11,23,57 In veterinary medicine, increased concentra-
tions of cTns have been observed in infectious disease patients,
trauma patients, GDV patients, and patients suffering from systemic
diseases25,26,28–30,58–62 and are correlated with poor prognosis in
some of these reports.25,26,28,30 Reports that evaluate plasma con-
centrations of cTnI and cTnT in dogs with SIRS have confirmed their
prognostic value, identifying differences in concentration between
survivors and nonsurvivors.19,20,33 In one report, additional sampling
to measure cTnI concentrations on day 2 or 3 (or evaluation of con-
centration changes) did not add value to the prognostic information.19
Although the incidence of increased cTnI concentrations has been
reported to be higher than for cTnT, cTnI and cTnT carried similar prog-
nostic information.20,33 cTnT concentrations have been established
as interesting markers to predict prognosis of canine SIRS patients,
but cutoff limits remain to be determined.33 As cTnT (and cTnI) can
remain increased up to 7 or 10 days after an insult, the kinetics of cTnT
are difficult to evaluate, and they may be less useful for evaluation of
disease progression.63,64
In the present study, NT-proBNP concentrations were not signif-
icantly correlated with prognosis. Previous studies in dogs tended to
evaluate natriuretic peptides at presentation, while higher concen-
trations should be expected later during hospitalization. This delay
in the rise of NT-proBNP limits its use as a prognostic marker in a
clinical veterinary emergency care setting. At later timepoints, the
group size in this study rapidly decreased, which may have impacted
the likelihood to identify significant differences between survivors and
nonsurvivors. A recently published meta-analysis in human patients
with sepsis concluded that NT-proBNP concentrations are signif-
icantly associated with risk of mortality.22 This meta-analysis also
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concluded that increased NT-proBNP concentrations in the presence
of SIRS or sepsis do not indicate cardiac dysfunction, but normal
NT-proBNP concentrations rule out the need for further cardiac
investigation.22 The lack of a significant difference in NT-proBNP con-
centration between survivors and nonsurvivors in this study should
be confirmed in a larger cohort of patients with SIRS. The observed
increased NT-proBNP concentrations in this study may be explained
by myocardial hibernation, but also may have been increased due
to increased cardiac wall stress after volume resuscitation,65 the
presence of lung injury, acute respiratory distress syndrome, or
thromboembolism.6
There are several limitations to the present study. Dogs that were
considered too unstable by the attending clinician were removed from
the study, and therefore, more severely ill patients were less likely to
enter the study. Consequently, findings might have been different if all
dogs were included, regardless of their clinical status. Because sam-
pling times were standardized with relation to the timing of presenta-
tion to the emergency department, disease may have been present for
variable amounts of timeprior to enrollment, and thismayhave altered
the kinetics of the studied biomarkers. In addition, a large proportion
of our patients were euthanized at the owner's request, rather than
basedon specific study endpoints,whichmayhave impacted our analy-
sis of prognosis. In order to avoid any effect of financial considerations
on the prognostic evaluation, all dogs that were euthanized for finan-
cial or unspecified reasons were removed from the prognosis analysis.
In the present study, 44 patients survived to discharge (64%), which is
similar to,66 or better than67 previous studies on clinical canine SIRS
patients.
Samples with NT-proBNP concentrations above the upper limit of
the assay (3,000 pmol/L) were not diluted to measure the exact con-
centration because of financial restrictions. Therefore, NT-proBNP
concentration was underestimated in some samples. This did not pro-
hibit the finding of significant changes, but may have underestimated
the degree of those changes in NT-proBNP concentration. Similarly, a
cTnT assay rather than a cTnI assay was used due to financial restric-
tions. The use of a cTnI assay may have resulted in a higher detection
rate of increased troponin concentrations.
Our study demonstrates that cardiac biomarkers are often
increased in dogs with SIRS presenting to the emergency department.
Additionally, this study confirms that the cTnT concentration was
associated with survival in dogs with SIRS. Studies investigating
the correlation of cardiac biomarkers with echocardiographic find-
ings and inflammatory cytokines in canine patients with SIRS are
warranted.
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